What is Stilla Technologies?
Founded in 2013 and based in Villejuif, France, Stilla Technologies is at the forefront of molecular diagnostics, offering a flexible digital PCR (dPCR) platform designed to accelerate the development and deployment of advanced genetic tests. The company's innovative technology empowers researchers and clinicians with precise and sensitive nucleic acid detection, crucial for applications ranging from oncology to infectious disease research. Stilla Technologies' commitment to innovation positions it as a key player in the rapidly evolving landscape of genetic analysis and personalized medicine.
How much funding has Stilla Technologies raised?
Stilla Technologies has raised a total of $76.7M across 4 funding rounds:
Angel/Seed
$135K
Series A
$19.5M
Series B
$22M
Debt
$35M
Angel/Seed (2014): $135K with participation from Wilco
Series A (2018): $19.5M led by BNP Paribas D�veloppement, Illumina Ventures, Paris Saclay Seeds, LBO France, Idinvest Partners, and Kurma Partners
Series B (2020): $22M supported by BNP Paribas Développement, Tus-Holdings Co. , Ltd., Illumina Ventures, Paris Saclay Seed Funds, Idinvest Partners, LBO France, and Kurma Partners
Debt (2021): $35.1M featuring LBO France, TusPark Capital Management, Kurma Partners, BNP Paribas Developpement, Illumina Ventures, Eurazeo, Casdin Capital, and European Investment Bank
Key Investors in Stilla Technologies
LBO France
LBO France is a leading investment fund with over 30 years of expertise in private equity, real estate, venture capital, and listed securities, focusing on mid-cap and small-cap investments and innovative sectors like digital health.
Kurma Partners
Kurma Partners is a key European player in the financing of innovation in healthcare and biotechnology, from pre-seed to growth capital, with a strong focus on innovative drug development approaches.
Illumina Ventures
Illumina Ventures is a leader in genomics and precision health investing, focused on building an ecosystem that translates investment into innovation to enhance human health.
What's next for Stilla Technologies?
With its recent strategic investment and substantial overall capital, Stilla Technologies is poised for significant expansion. The company is expected to leverage this financial backing to further enhance its dPCR platform, broaden its market reach, and potentially explore new therapeutic areas or diagnostic applications. This funding will likely fuel research and development initiatives, scale manufacturing capabilities, and strengthen its commercial operations, solidifying its competitive edge in the biotechnology sector.
See full Stilla Technologies company page
